Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Imdatifan in Locally Advanced Clear Cell Renal Cell Carcinoma: NCT06049030 Clinical Landscape Report 2026
16 October 2026
NCT06049030 clinical landscape for Locally Advanced Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Denocabtagene Ciloleucel in Diffuse large B-cell lymphoma refractory: NCT06047197 Clinical Landscape Report 2026
16 October 2026
NCT06047197 clinical landscape for Diffuse large B-cell lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Polatuzumab Vedotin-Piiq in Large B-cell lymphoma: NCT06047080 Clinical Landscape Report 2026
16 October 2026
NCT06047080 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Acasunlimab in Advanced Endometrial Carcinoma: NCT06046274 Clinical Landscape Report 2026
16 October 2026
NCT06046274 clinical landscape for Advanced Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ALETA-001 in Follicular Lymphoma: NCT06045910 Clinical Landscape Report 2026
16 October 2026
NCT06045910 clinical landscape for Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JY-231 in B-Cell Lymphoma: NCT06045585 Clinical Landscape Report 2026
16 October 2026
NCT06045585 clinical landscape for B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in T-cell/histiocyte rich large B-cell lymphoma: NCT06045247 Clinical Landscape Report 2026
16 October 2026
NCT06045247 clinical landscape for T-cell/histiocyte rich large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
C-13-60 in Locally Advanced Cholangiocarcinoma: NCT06043466 Clinical Landscape Report 2026
16 October 2026
NCT06043466 clinical landscape for Locally Advanced Cholangiocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
Ipilimumab in Metastatic Renal Cell Carcinoma: NCT06049576 Clinical Landscape Report 2026
16 October 2026
NCT06049576 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ferrous Gluconate in Endometrial Carcinoma: NCT06049693 Clinical Landscape Report 2026
16 October 2026
NCT06049693 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Glofitamab in T-cell/histiocyte rich large B-cell lymphoma: NCT06050694 Clinical Landscape Report 2026
16 October 2026
NCT06050694 clinical landscape for T-cell/histiocyte rich large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Nivolumab in Renal Medullary Carcinoma: NCT06053658 Clinical Landscape Report 2026
16 October 2026
NCT06053658 clinical landscape for Renal Medullary Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.